PharmaPoint: Macular Edema and Macular Degeneration – 5EU Drug Forecast and Market Analysis to 2023
Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.
The new therapies entering the AMD market will be the main driver of growth in this market, with the wAMD drugs Fovista, squalamine, and abicipar pegol launching into the French market in 2017, 2018, and 2020, respectively. GlobalData estimates that the combined drug sales for ME and AMD in Italy during 2013 reached $348m.
– Overview of Macular Edema and Macular Degeneration including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
– Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
– Sales forecast for the top drugs in 5EU from 2013-2023.
– Analysis of the impact of key events as well the drivers and restraints affecting 5EU Macular Edema and Macular Degeneration market.
Reasons To Buy
– Understand and capitalize by identifying products that are most likely to ensure a robust return
– Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration
– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
– Make more informed business decisions from insightful and in-depth analysis of drug performance
– Obtain sales forecast for drugs from 2013-2023 in 5EU.
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
For more information visit, Radiant Insights
Corporate Sales Specialist, USA
Radiant Insights, Inc
Toll Free: 1-888-202-9519